[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ain Shams University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":637},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,277,0,25,[9,45,78,104,127,149,173,198,225,250,275,296,324,349,370,397,417,443,469,495,521,545,563,589,617],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651434","red-cell-distribution-widthalbumin-ratio-as-a-predictive-tool-for-mortality-of-patients-with-burn-injuries-100651434",false,"NCT07761845","Red Cell Distribution Width\u002FAlbumin Ratio as a Predictive Tool for Mortality of Patients With Burn Injuries","Measurement of Red Cell Distribution Width\u002FAlbumin Ratio as a Predictive Tool for 30-day Mortality of Patients With Burn Injuries","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Both sexes.\n* Patients with burn injuries (%TBSA \\>20%).\n* Availability of complete laboratory data (RDW, albumin) on admission.\n* Admission to ICU within 24 hours of burn injury.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Patients with chronic hematologic disease.\n* Pre-existing liver disease.\n* Nephrotic syndrome.\n* patients on chemotherapy.\n* Patients with incomplete or missing lab records.\n* Pregnant females.\n* Patient or guardian refusal.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","30 Days","OBSERVATIONAL","The aim of this study is to evaluate the prognostic utility of the red cell distribution width\u002Falbumin ratio (RAR), measured within 24 hours of hospital admission, in predicting 30-day mortality among patients with burn injuries.",[26],"Burn Injuries",[28,29,30,31],"burn","mortality","albumin","Red Cell Distribution Width","RECRUITING","2026-08-15",{"date":35,"type":36},"2026-08-18","ACTUAL",{"date":38,"type":36},"2026-08-01",{"date":40,"type":21},"2027-04-01",{"name":42,"class":43},"Ain Shams University","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100650512","phase-2-hyaluronic-acid-vs-i-prf-with-microneedling-in-enhancing-peri-implant-soft-tissue-100650512","NCT07750756","Hyaluronic Acid vs I-PRF With Microneedling in Enhancing Peri-implant Soft Tissue","Hyaluronic Acid Versus I-PRF Combined With Microneedling for Peri Implant Soft Tissue Enhancement: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with delayed implants placed in the maxillary esthetic region in correct positioning and angulation\n* Patients with peri-implant gingival thickness ≤ 1 mm\n* Patients with healthy gingiva and who can maintain good oral hygiene around implants\n\nExclusion Criteria:\n\n* Marginal bone loss ≤ 2 mm\n* Patients with peri-implantitis or periodontitis\n* Patients with systemic conditions or diseases impairing healing or soft tissue metabolism\n* Pregnant or lactating females\n* Patients taking medications affecting the gingiva","21 Years","50 Years",{"count":55,"type":21},42,"INTERVENTIONAL",[58,59],"PHASE2","PHASE3","This study aims to compare the use of microneedling alone versus with hyaluronic acid or i-PRF in conjunction with microneedling in peri-implant mucosa in the esthetic zone to test the superior increase in gingival thickness.",[62],"Peri-implant Mucosa Thickness",[64,65,66,67,68],"microneedling","hyaluronic acid","I-PRF","gingival thickness","peri-implant","NOT_YET_RECRUITING","2026-08-14",{"date":72,"type":36},"2026-08-17",{"date":74,"type":21},"2026-10-30",{"date":76,"type":21},"2028-05-30",{"name":42,"class":43},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100651969","phase-2-the-effect-of-l-carnitine-on-wound-healing-in-patients-with-diabetic-foot-ulcer-100651969","NCT07768228","The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.","Inclusion Criteria:\n\n* Adult Male or Female patients with diabetic neuropathy mean age (30-75) years old.\n* Having Diabetic neuropathy and Diabetic foot ulcer grade 1-2 (mild- moderate) according to Wagner classification.\n* Uncontrolled diabetic patients (HbA1c). \\\u003C 9 duration of diabetic (5 - 10) years.\n* All patient treated with stable dose of anti-diabetic medication priors and during the period of the study.\n\nExclusion Criteria:\n\n* Patients with other causes of ulcers.\n* Patient taking any antioxidant supplements including vitamin E, ascorbic acid, omega 3 fatty acid, Coenzyme Q10 within three months prior to enrollment in the study.\n* Patient with autoimmune disease.\n* Patient with liver disease or kidney disease.\n* Patient taking medications for cancer.\n* Patient with thyroid disease.","30 Years","75 Years",{"count":87,"type":21},50,[58],"Primary outcome: To evaluate the efficacy of L-Carnitine supplementation on length and depth ulcer size\n\nSecondary outcome: To investigate the effect of L-Carnitine supplements on:\n\n1. Vascular endothelial growth factor (VEGF)\n2. Inflammatory markers TNF-a (Tumor necrosis factor alpha).\n3. Hemoglobin A1C (HbA1c) And Lipid profile (cholesterol, triglycerides, high-density Lipoprotein (HDL) and low-density lipoprotein (LDL)).\n4. To assess the type and likelihood of any adverse drug reaction that can be related to L-Carnitine supplementation.\n5. QOL (DIABETES 39)",[91,92],"Diabetic Foot Ulcer","Diabetic Foot Ulcer (DFU)",[94,91,95],"L-Carnitine","DFU","2026-08-13",{"date":72,"type":36},{"date":99,"type":21},"2026-09-01",{"date":101,"type":21},"2027-08-01",{"name":42,"class":43},2,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":111,"targetDuration":4,"studyType":56,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100651803","phase-2-lactoferrin-supplementation-in-diabetic-nephropathy-100651803","NCT07764991","Lactoferrin Supplementation in Diabetic Nephropathy","The Effect of Lactoferrin on the Clinical Outcome of Patients With Diabetic Nephropathy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml\u002Fmin\u002F1.73m2) or stage 4 (eGFR 15-29 ml\u002Fmin\u002F1.73m2)\n* Urinary albumin\u002FCreatinine ratio (UACR): moderately and severely increased albuminuria (\\> 30 mg\u002Fg)\n* Stable standard therapy for at least three months prior to inclusion in the study.\n* Life expectancy \\>12 months.\n\nExclusion Criteria:\n\n* Participation in other interventional trials\n* Current or previous treatment with LF supplements at least three months before inclusion.\n* Kidney donor or recipient\n* Pregnancy or breastfeeding\n* Active malignancy\n* Poor adherence potential (e.g. cognitive impairment, psychiatric instability)\n* Known intolerance or allergy to lactoferrin",{"count":112,"type":21},60,[58],"Multiple pathways and mediators, including oxidative stress, inflammation, and the over-activity of the renin-angiotensin-aldosterone system are involved in the development of albuminuria and progression of diabetic nephropathy (DN), of which oxidative stress is the most prominent. Previous research has shown that lactoferrin (LF) has multi-pharmacological properties, including antioxidant, anti-inflammatory, antiviral, anticancer, antibacterial, antifibrotic and immunogenic properties . Lactoferrin was reported to be a useful nutritional supplement to support immunity and antioxidant status and suppress systemic inflammatory and oxidative stress biomarkers ( ↓ TNF-α, ↓ IL-6, ↓ IFN-γ, ↓ IL-1β, ↑ IL-10) in previous studies. Lactoferrin, in vitro, has been reported to reduce oxidative stress, inflammation, apoptosis and fibrosis in acute and chronic kidney disease. Moreover, different rat models with kidney injury have proven the nephroprotective effect of LF through decreasing the levels of urinary albumin to creatinine ratio, serum creatinine, serum urea, and blood urea nitrogen (BUN) and also through reducing the expression of kidney damage markers; osteopontin, renin and IL-6. Furthermore, LF improved glycemic control and lipid markers through significant improvement of HbA1c, FBG, insulin resistance, body mass index and lipid markers.\n\nHence, this study aims to evaluate the effect of LF on the clinical outcomes of type 2 diabetic patients with DN.",[116],"Diabetic Nephropathy",[118,119],"lactoferrin","diabetic nephropathy","2026-08-10",{"date":70,"type":36},{"date":123,"type":36},"2025-08-01",{"date":125,"type":21},"2027-02",{"name":42,"class":43},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":56,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":44},"100651652","efficacy-and-safety-of-flexible-ureteroscopy-with-flexible-navigable-suction-ureteral-access-sheath-versus-mini-percutaneous-nephrolithotomy-with-vacuum-assisted-access-sheath-100651652","NCT07763743","Efficacy and Safety of Flexible Ureteroscopy With Flexible Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheath","A Comparative Study on the Efficacy and Safety of Flexible Ureteroscopy With Flexible Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheath for the Management of Renal Stones 1- 2.5 cm in Pediatric Age Group","Inclusion Criteria:\n\n\\- Renal stone burden 1- 2.5 cm confirmed by imaging (CT or ultrasound).\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the study.\n* Untreated Urinary tract infection (UTI) proved by urine culture and sensitivity.\n* Uncorrected coagulopathy.\n* Anatomical anomalies or ureteral stricture precluding either surgical approach.\n* Previous surgical intervention on the same kidney.","1 Year","14 Years",{"count":137,"type":21},72,[139],"NA","Mini-percutaneous nephrolithotomy (mini-PCNL) and retrograde intrarenal surgery (RIRS) are both effective treatment modalities for renal calculi measuring up to 2.5 cm in pediatric patients, demonstrating similar efficacy and complication profiles.\n\nSuction has emerged as a potentially transformative adjunct in both percutaneous nephrolithotomy (PCNL) and RIRS. Recent studies evaluating various suction mechanisms during RIRS and mini-PCNL have demonstrated multiple benefits, including reduced operative time, higher stone-free rates (SFR), decreased intrarenal pressure (IRP) and temperature, as well as enhanced intraoperative visualization.\n\nBoth FANS-UAS in RIRS and VAAS in Mini-PCNL have shown promising outcomes in the pediatric population. Taken together, these findings suggest that suction-assisted technologies whether in RIRS or Mini-PCNL enhance both efficacy and safety in pediatric stone management.",[142],"Pediatric Renal Stones",{"date":96,"type":36},{"date":145,"type":36},"2026-06-01",{"date":147,"type":21},"2027-06-10",{"name":42,"class":43},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":156,"minAge":157,"maxAge":18,"enrollmentInfo":158,"targetDuration":4,"studyType":56,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":170,"leadSponsor":172,"locationsCount":44},"100651184","efficacy-of-prf-in-hypospadias-repair-100651184","NCT07757828","Efficacy of PRF in Hypospadias Repair","Evaluating the Efficacy of Platelet-Rich Fibrin (PRF) in Hypospadias Repair: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with primary distal or mid-penile hypospadias.\n* Eligible for first-time (primary) surgical repair using the TIP (Tubularized Incised Plate) technique.\n\nExclusion Criteria:\n\n* previous hypospadias surgery.\n* Associated severe chordee requiring staged repair or patient with crippled hypospadias.\n* Children with systemic diseases that may impair wound healing (e.g., diabetes, immunodeficiency, malnutrition).\n* Presence of bleeding or coagulation disorders.\n* Medically Unfit for surgery.","MALE","6 Months",{"count":159,"type":21},80,[139],"Hypospadias is an anomaly characterized by an ectopic ventral urethral meatus, and an incomplete or hooded prepuce. Its incidence is estimated at 1 in 200-300 live male births, with variations across populations and severity types.\n\nSuccessful hypospadias repair depends largely on optimal tissue healing and robust vascular support around the neourethra. Thus, many adjunctive techniques have been investigated to improve outcomes, including dartos flaps, tunica vaginalis flaps, and various tissue sealants.\n\nIn recent years, attention has turned toward biological augmentation strategies, particularly the use of platelet-rich plasma (PRP) and platelet-rich fibrin as a potential enhancer of wound healing.\n\nPlatelet-rich fibrin (PRF), a second-generation autologous platelet concentrate, has recently emerged as another promising biologic in tissue engineering.\n\nThis study aims to evaluate the effect of PRF application in primary hypospadias repair surgery and determine its effect in improving healing and reduction of postoperative complications.",[163],"Hypospadias",[163,165,166],"PRF","Repair",{"date":168,"type":36},"2026-08-11",{"date":38,"type":21},{"date":171,"type":21},"2027-10-01",{"name":42,"class":43},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":180,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":56,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":197,"locationsCount":44},"100650866","phase-2-effects-of-curcumin-piperine-supplementation-in-fibromyalgia-100650866","NCT07753018","Effects of Curcumin-Piperine Supplementation in Fibromyalgia","Evaluation of the Effect of Curcumin and Piperine Supplementation on Clinical Outcome in Fibromyalgia Patients.","Inclusion Criteria:\n\n* Adult women aged ≥18 years.\n* Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.\n\nExclusion Criteria:\n\n* Diabetic patients (HbA1c ≥ 6.5).\n* Patients with chronic inflammatory or autoimmune diseases other than FM.\n* Patients allergic to curcumin or piperine.\n* Patients receiving other anti-inflammatory medications.\n* Severe hepatic or renal impairment.\n* Patients receiving anticoagulant medications (e.g., clopidogrel).\n* Pregnancy or lactation.\n* Participation in another clinical trial","FEMALE",{"count":159,"type":21},[58],"The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.\n\nParticipants will:\n\nBe randomly assigned to receive either curcumin and piperine supplements or a placebo.\n\nAttend scheduled clinic visits for clinical assessments and blood sample collection.\n\nComplete study questionnaires before and after treatment time frame.\n\nThe primary question the study aim to answer is:\n\nDoes Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?\n\nThe secondary questions this study aims to answer are:\n\nDoes supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?",[185],"Fibromyalgia (FM)",[187,188,189,190,191,192],"Fibromyalgia syndrome","Curcumin- Piperine","MDA","Insulin Resistance","Inflammation","Oxidative stress","2026-08-09",{"date":168,"type":36},{"date":38,"type":21},{"date":101,"type":21},{"name":42,"class":43},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":56,"phases":207,"briefSummary":208,"conditions":209,"keywords":214,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":44},"100651699","outcomes-of-iliac-vein-stenting-with-dedicated-venous-stents-in-treatment-of-chronic-post-thrombotic-venous-ulcers-100651699","NCT07762222","Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous Ulcers","Inclusion Criteria:\n\n* Chronic non-healing venous ulcer associated with iliofemoral post-thrombotic syndrome.\n* CEAP clinical classification C6.\n* Iliofemoral post-thrombotic venous obstruction confirmed by appropriate venous imaging.\n* Age 18 years or older.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Nonthrombotic iliac vein lesion (NIVL).\n* Post-phlebitic femoropopliteal venous lesions with a patent iliac vein.\n* CEAP clinical classification other than C6.\n* Previous venous intervention.\n* Active pathological ulcer unrelated to post-thrombotic venous disease.\n* Life expectancy less than 2 years.\n* Pregnancy.\n* Known allergy to contrast media.\n* Contraindication to anesthesia.\n* Refusal to participate or inability to provide informed consent.","70 Years",{"count":206,"type":21},20,[139],"Outcomes of iliac vein stenting with dedicated venous stents in treatment of chronic post-thrombotic venous ulcers Deep vein thrombosis (DVT) affects 1 to 3 individuals per 1000 annually. Among these patients, 20% to 50% may develop post-thrombotic syndrome (PTS), with the likelihood varying based on the extent and location of the thrombus. Notably, despite receiving anticoagulation therapy, 5% to 10% of patients may progress to severe PTS, potentially leading to the development of venous ulcers (Afsha Aurshina, 2018). Chronic venous obstruction (CVO) refers to the impediment of venous flow, typically resulting from either partial or complete blockage of the venous system. This obstruction leads to diminished venous flow and elevated pressure within the affected veins. CVO serves as a broad descriptor for various conditions, including post-thrombotic syndrome (PTS) and nonthrombotic iliac vein lesions (NIVLs). PTS commonly arises as a complication of deep vein thrombosis (DVT), with estimates indicating that up to 50% of patients diagnosed with iliofemoral DVT will develop PTS within two years following their initial diagnosis. (Mohammad E. Barbati, 2024)\n\nThe study aims to know the outcomes of iliac vein stenting with dedicated venous stenting in the treatment of post-thrombotic syndrome venous ulcer.\n\nType of Study: Prospective single arm cohort study\n\n* Study Setting: Ain Shams University hospitals\n* Study Period: 2 years with 6 months follow up\n* Sample Size: 20 patients.\n* Study Population Patients presenting to the outpatient clinic at Ain Shams University Hospitals with venous ulcers.\n* Study Tools\n\n  * 20 patients will be selected.\n  * Written informed consent.\n  * Full history taking, personal history , risk factors of DVT, presence of any medical illness , assessment of QOL based on CVIQ 20 - questionnaire, list of symptoms, sensations or types of discomfort that you may or may not be experiencing and which may make everyday life hard to bear to a greater or lesser extent.\n  * Clinical evaluation: based on revised Venous Clinical Severity Score rVCSS , Villalta score and CEAP classification . rVCSS includes 10 items, such as pain, varicose veins, oedema, skin pigmentation, inflammation, skin induration, number of active ulcers, ulcer size, duration of ulcer, and application of pressure therapy. Each item is scored from 0 to 3 according to the severity, and the total score is 30. A higher score indicates higher severity. And using villlata score It can be used to both diagnose and categories the severity of the condition. The Villalta score involves both the patient who grades the presence and severity (0-3 points) of five symptoms ( pain , cramps, heaviness, parasthesia and pruritus ) and and the physician who grades six clinical signs(Pre-tibial oedema, Hyper-pigmentation, Redness, Venous Ectasia, ain on calf compression, ulcers) (0-3 points) after examination of the lower limb. Also the clinical severity of the venous disease will be graded according to the clinical, etiological, anatomical, and pathophysiological (CEAP) scoring system, and assessment of venous ulcer assessment (by onset, course, duration, site, size, shape",[210,211,212,213],"Vascular","DVT - Deep Vein Thrombosis","Post Thrombotic Syndrome","Venous Ulcer of Leg",[215,216,217],"iliofemoral postthrombotic syndrome","venous ulcer","dedicated iliac venous stenting","2026-08-08",{"date":96,"type":36},{"date":221,"type":36},"2025-03-02",{"date":223,"type":21},"2027-01-01",{"name":42,"class":43},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":204,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100650070","stroke-volume-versus-inferior-vena-cava-collapsibility-index-to-predict-postinduction-hypotension-in-intestinal-obstruction-100650070","NCT07742904","SV and IVC Collapsibility Index to Predict Postinduction Hypotension","Stroke Volume Versus Inferior Vena Cava Collapsibility Index to Predict Postinduction Hypotension in Intestinal Obstruction","Inclusion Criteria:\n\n* Adult patients with intestinal bowel obstruction undergoing exploratory abdominal surgery under general anesthesia.\n* Age 40 to 70 years old.\n* Body Mass Index (BMI) = 18 to 25 kg\u002Fm2.\n* American Society of Anesthesiologists (ASA) physical status grade I or II.\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status grade \\>= III.\n* Patients in whom the IVC cannot be visualized or patients with poor echogenicity.\n* Patients with hemodynamic instability.\n* Patients with vascular, respiratory, or cardiac diseases (e.g., cardiomyopathy, heart valve disease, arrhythmia, or bad exercise tolerance).\n* Pregnant patients.\n* Difficult airway or multiple intubatio","40 Years",{"count":234,"type":21},75,"Postinduction hypotension (PIH) is a frequent complication during general anesthesia. This study aims to compare the predictive effectiveness and diagnostic accuracy of stroke volume (SV) measured via left ventricular outflow tract velocity time integral (LVOT-VTI) versus the inferior vena cava collapsibility index (IVC-CI) using transthoracic echocardiography. The assessment will be conducted in adult patients with intestinal obstruction undergoing exploratory abdominal surgery under general anesthesia.",[237,238],"Post-induction Hypotension","Intestinal Obstruction",[240,241,242,243,244],"Stroke Volume","Inferior Vena Cava Collapsibility Index","LVOT-VTI","Echocardiography","General Anesthesia",{"date":168,"type":36},{"date":38,"type":21},{"date":248,"type":21},"2027-02-01",{"name":42,"class":43},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":265,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100651174","2d4d-ratio-in-relation-to-anxiety-and-stress-among-anesthesiology-residents-100651174","NCT07757971","2D:4D Ratio in Relation to Anxiety and Stress Among Anesthesiology Residents","Association of Second-to-Fourth Digit Ratio (2D:4D) With Trait Anxiety and Occupational Stress Among Anesthesiology Residents: A Cross Sectional Observational Study","Inclusion Criteria:\n\n* Any anesthesiologists who voluntarily agreed to participate in the study.\n* Age: 20-35 years\n* Both genders\n\nExclusion Criteria:\n\n* Incomplete questionnaires and\u002For irrelevant responses.\n* Injuries to the 2nd or 4th digits,\n* Unclear or inaccurate digit photocopy,\n* If the participant is a twin\n* Cumulative leave (e.g., maternity\u002Fsick leave) exceeding 6 months during the study period;\n* Pre-existing diagnosis of psychiatric disorders prior to the study","20 Years","35 Years",{"count":260,"type":21},116,"Anesthesiologists are exposed to substantial occupational stress, making their psychological well-being essential for both personal health and optimal patient care. Early identification of mental health disorders among healthcare professionals is important for improving well-being and maintaining healthcare quality.",[263,264],"Anxiety","Stress",[266,267],"anxiety","stress","2026-08-05",{"date":168,"type":36},{"date":271,"type":21},"2026-09-15",{"date":273,"type":21},"2026-12-30",{"name":42,"class":43},{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":281,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":56,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100650031","trueness-of-intra-oral-scanners-compared-to-an-extra-oral-scanner-for-scanning-of-mandibular-edentulous-impressions-100650031","NCT07740798","Trueness of Intra-Oral Scanners Compared to an Extra-Oral Scanner for Scanning of Mandibular Edentulous Impressions","Inclusion Criteria:\n\n* edentulous patients\n* last teeth extraction 6 months before the impression procedures\n\nExclusion Criteria:\n\n* un cooperative patients\n* Neuromotor disorders\n* Parkinsonism\n* Tremors",true,{"count":283,"type":21},9,[139],"the relative accuracy of different intraoral scanner types specifically for capturing the complex morphology of edentulous arches, including peripheral borders and mobile tissues, remains an area of investigation, with conflicting reports in the literature.\n\nThe purpose of this study is to compare the accuracy of different intraoral scanners with a laboratory scanner for digitizing impressions of edentulous mandible.\n\nCompletely edentulous patients will be gathered; final impressions will be taken for them using zinc oxide \\& eugenol impression material then they will be scanned with intra oral and extra oral scanners for indirect digitalization.\n\nScans will be superimposed and compared using a software program for analysis for accuracy in the form of trueness",[287],"Edentulous Jaw","2026-08-03",{"date":290,"type":36},"2026-08-04",{"date":292,"type":21},"2026-07-15",{"date":294,"type":21},"2026-10-15",{"name":42,"class":43},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":303,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":56,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":44},"100650190","ligation-of-intersphincteric-fistula-tract-versus-cyanoacrylate-glue-in-one-stage-management-of-high-transsphincteric-perianal-fistula-100650190","NCT07744672","Ligation of Intersphincteric Fistula Tract Versus Cyanoacrylate Glue in One-Stage Management of High Transsphincteric Perianal Fistula","Ligation of Intersphincteric Fistula Tract Versus Cyanoacrylate Glue in One-Stage Management of High Transsphincteric Perianal Fistula: A Randomized Controlled Trial","Inclusion Criteria:\n\nAge ≥ 16 years MRI-confirmed high transsphincteric perianal fistula Fit for surgery (ASA I-III)\n\nExclusion Criteria:\n\n* Crohn's disease\n* Tuberculosis or malignancy-associated fistula\n* Horseshoe fistula\n* Previous definitive fistula surgery (excluding drainage procedures)\n* Pregnancy\n* Immunocompromised state (e.g., HIV, chronic steroid use, chemotherapy)\n* Uncontrolled diabetes mellitus (HbA1c \\> 8% )\n* Active, undrained perianal sepsis\u002Fabscess at the time of scheduled surgery","16 Years",{"count":112,"type":21},[139],"This study aims to compare ligation of the intersphincteric fistula tract with cyanoacrylate glue in the management of high transsphincteric perianal fistula.",[308],"High Transsphincteric Perianal Fistula",[310,311,312,313,314,315,316],"LIFT","ligation of intersphincteric fistulous tract","CAG","cyanoacrylate glue","perianal fistula","rondomized controlled trial","sphincter perserving surgery","2026-08-02",{"date":290,"type":36},{"date":320,"type":36},"2025-09-15",{"date":322,"type":21},"2027-04-20",{"name":42,"class":43},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":56,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":44},"100649620","phase-2-protective-role-of-alpha-lipoic-acid-in-chemotherapy-induced-mucositis-100649620","NCT07736495","Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis","Evaluation of the Protective Effect of Alpha-Lipoic Acid Against 5-Fluorouracil-Induced Oral Mucositis in Colorectal Cancer Patients","Inclusion Criteria:\n\n1. Age \\>18 years.\n2. Newly diagnosed chemotherapy naive CRC patients\n3. Planned to receive FOLFOX-6 protocol as adjuvant, neoadjuvant or palliative therapy.\n4. Adequate liver function (liver transaminases level \\\u003C 3 times upper normal limits and total bilirubin \\\u003C 1.5 times upper normal limits).\n5. Adequate kidney function (estimated glomerular filtration rate \\>60 ml\u002Fmin).\n6. Adequate bone marrow function (WBCs count \\> 3000 cells\u002Fmm3, ANC count \\>1500 cells\u002Fmm3 and platelets count \\> 100,000 cells\u002Fmm3).\n\nExclusion Criteria:\n\n1. Presence of other primary cancers.\n2. Treatment with ALA for any other indication.\n3. Allergy to ALA.\n4. Pregnant or lactating women.\n5. Patients with previous mucositis for any reason.\n6. Patients who cannot tolerate oral intake.\n7. Patients receiving other dietary antioxidant supplements.",{"count":87,"type":21},[58,59],"Colorectal cancer (CRC) represents one of the most common cancers worldwide and 5-Fluorouracil (5-FU) is still the mainstay of treatment. However, 5-FU is often implicated in inducing oral mucositis (OM), a painful inflammatory condition that may hinder oral intake, negatively impact quality of life and disrupt adherence with cancer treatment.\n\nOxidative stress and inflammation play a vital role in OM pathogenesis. Alpha-lipoic acid (ALA) is a powerful antioxidant and anti-inflammatory agent that has demonstrated protective effects towards chemotherapy-induced mucosal damage in preclinical studies.\n\nTherefore, ALA may be a promising strategy to minimize or avoid 5-FU-induced oral mucositis in patients with colorectal cancer, which deserves additional clinical investigation.",[335],"Colorectal Cancer",[337,338,339,340,192,191],"Alpha lipoic acid","Colorectal cancer","Oral Mucositis","5-Fluorouracil","2026-07-29",{"date":343,"type":36},"2026-07-30",{"date":345,"type":36},"2026-07-27",{"date":347,"type":21},"2026-12-29",{"name":42,"class":43},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":180,"minAge":232,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":56,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":44},"100649835","a-comparative-study-between-opioid-free-general-anaesthesia-and-opioid-based-general-anaesthesia-on-the-quality-of-recovery-in-patients-undergoing-elective-laparoscopic-hystrectomy-a-randomized-trial-100649835","NCT07739641","A COMPARATIVE STUDY BETWEEN OPIOID-FREE GENERAL ANAESTHESIA AND OPIOID-BASED GENERAL ANAESTHESIA ON THE QUALITY OF RECOVERY IN PATIENTS UNDERGOING ELECTIVE LAPAROSCOPIC HYSTRECTOMY: A Randomized Trial","Inclusion Criteria:\n\n* Undergoing a scheduled laparoscopic hysterectomy surgery under general anaesthesia.\n* Age group: 40-65 years old.\n* BMI\\\u003C35.\n* ASA I-II.\n\nExclusion Criteria:\n\n* Emergency hysterectomy.\n* Allergy to any of the drugs used in the study.\n* HR \\\u003C 50 bpm (chronic treatment by beta blockers, heart block patients).\n* Alcohol or drug abuse.\n* Psychiatric disease.\n* Liver impairment. Kidney impairment","65 Years",{"count":357,"type":21},66,[139],"the intent of this study To compare the efficacy of opioid free general anaesthesia versus opioid based general anaesthesia to achieve enhanced recovery regarding post-operative pain and post-operative nausea and vomiting episodes in patients undergoing elective laparoscopic hysterectomy",[361,362,363],"Post Operative Recovery","Post Operative Nausea and Vomiting (PONV)","Post Operative Analgesia",{"date":365,"type":36},"2026-07-31",{"date":367,"type":21},"2026-08-22",{"date":322,"type":21},{"name":42,"class":43},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":180,"minAge":303,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":379,"conditions":380,"keywords":386,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":396,"locationsCount":44},"100572088","ultrasound-detection-of-body-composition-in-critical-care-100572088","NCT06728722","Ultrasound Detection of Body Composition in Critical Care","Detection of the Changes in Body Composition of Critically Ill Obstetrics by Ultrasound and the Co-relations With Clinical Outcomes; a Prospective Observational Study.","Inclusion Criteria:\n\n* females with age 16 with no upper limit\n* American Society of Anesthesiologists (ASA) class I, II or III,\n* admitted to the obstetrics and Gynecology critical care unit\n\nExclusion Criteria:\n\n* Patient refusal",{"count":378,"type":21},121,"Objective assessment of the Changes in body composition of critically ill patients is very valuable. Ultrasound stands as a solution due to its portability, bedside availability, and radiation-free technology. Those criteria are crucial for critically ill obstetrics and gynecological cases.",[381,382,383,384,385],"Muscle Loss","Extracellular Fluid Alteration","Critical Illness","Pregnancy Complications","Gynecologic Disease",[387,388,389,390],"ultrasound","body composition","critical illness","peripartum and gynecological cases",{"date":392,"type":36},"2026-07-28",{"date":394,"type":36},"2024-12-15",{"date":99,"type":21},{"name":42,"class":43},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":44},"100649175","long-term-follow-up-of-transvaginal-cystocele-repair-using-four-armed-collagen-coated-polyester-mesh-100649175","NCT07730749","Long Term Follow Up Of Transvaginal Cystocele Repair Using Four Armed Collagen Coated Polyester Mesh","Long Term Follow Up Of Transvaginal Cystocele Repair Using Four Armed Collagen Coated Polyester Mesh; Retrospective Cohort Study With Prospective Long-term Follow-up","Inclusion Criteria:\n\n• Data of patients who underwent transvaginal cystocele repair using four-armed collagen coated polyester mesh\n\nExclusion Criteria:\n\n* Patients with insufficient postoperative follow-up data.\n* Patients with incomplete or missing medical records.\n* Patients undergone radiation, laser therapy, or chemotherapy in the pelvic area postoperatively.\n* Patients newly discovered uncontrolled diabetes mellitus.",{"count":206,"type":21},"This study aims to assess safety and efficacy of transvaginal repair of cystocele using four armed collagen coated polyester mesh beyond 5 years postoperatively.",[407,408,409,410],"Long Term Follow-Up","Transvaginal Cystocele Repair","Four Armed Collagen","Polyester Mesh","2026-07-23",{"date":392,"type":36},{"date":414,"type":36},"2026-06-29",{"date":273,"type":21},{"name":42,"class":43},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":56,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":44},"100649165","phase-2-the-effect-of-nicorandil-on-rheumatoid-arthritis-patients-100649165","NCT07730723","The Effect of Nicorandil on Rheumatoid Arthritis Patients","The Effect of Nicorandil on Disease Activity in Rheumatoid Arthritis Patients","Inclusion Criteria:\n\n* Adult (≥18 years).\n* Confirmed diagnosis with RA according to ACR\u002FEULAR 2010 criteria.\n* Moderate to severe disease activity (DAS-28 ˃ 3.2).\n* Stable on conventional treatment for at least 3 months.\n* Adequate kidney and liver function.\n\nExclusion Criteria:\n\n* Other autoimmune diseases\n* Poor patient compliance\n* Malignancy or history of malignancy\n* Pregnancy or lactation.\n* Patients receiving bDMARDs or tsDMARDs.\n* Hypersensitivity to nicorandil.\n* Left ventricular heart failure or severe hypotension (SBP ˂100 mmHg).\n* History of cardiogenic shock.\n* History or active gastric ulcer.\n* Use of drugs contraindicated with nicorandil (e.g., sildenafil, tadalafil, vardenafil, tricyclic antidepressants, or guanyl cyclase).",{"count":425,"type":21},70,[58,59],"The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil. The main questions it aims to answer are:\n\n* Could nicorandil improve disease severity and symptoms of rheumatoid arthritis?\n* Does nicorandil lower the number of times participants need to use pain relieve medications?\n* Does the nicorandil improve participants functionality and ability to carry out daily activity?\n* Does nicorandil correct disease-associated damage and inflammation?\n* What side effects do participants have when taking nicorandil? Researchers will compare nicorandil to a placebo (a look-alike substance that contains no drug) to see if nicorandil works to decrease symptoms and severity of rheumatoid arthritis.\n\nParticipants will:\n\n* Take nicorandil or a placebo two times daily for 3 months\n* Visit the clinic once every month for checkups\n* Keep a diary of their symptoms and the number of times they use a pain reliever",[429],"Rheumatoid Arthritis (RA)",[429,431,191,432,433,434,435,436],"Nicorandil","DAS-28","Disease activity","Autoimmune disease","HAQ-DI","Quality of life",{"date":392,"type":36},{"date":439,"type":21},"2026-08",{"date":441,"type":21},"2027-07",{"name":42,"class":43},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":450,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":56,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":44},"100648623","tamsulosin-monotherapy-versus-combination-therapy-with-tadalafil-25-mg-vs-5-mg-in-managing-male-luts-secondary-to-bph-100648623","NCT07722884","Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH","Safety and Efficacy of Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH","Inclusion Criteria:\n\n* Patients older than 45 years of age.\n* Clinical diagnosis of benign prostatic hyperplasia (BPH) and moderate to severe lower urinary tract symptoms (LUTS) \\[International Prostate Symptom Score (IPSS) ≥ 13\\].\n* Maximum flow rate (Qmax) ≤ 15 mL\u002Fs, prostate volume ≥ 30 mL by transrectal ultrasound.\n\nExclusion Criteria:\n\n* Patients taking α-blockers, beta-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 (PDE5) inhibitors, anticholinergics, or nitrates were excluded.\n* Patients with a history of prostate or bladder surgery, lower urinary tract procedures, prostate or bladder cancer, neurological conditions affecting bladder function, severe cardiovascular disease, hepatic impairment, diabetes mellitus with complications, kidney dysfunction (acute or chronic), neurogenic bladder, or congenital urinary anomalies.\n* Additionally, patients with recent myocardial infarction, unstable angina, severe heart failure, uncontrolled hypertension, Prostate-Specific Antigen (PSA)\\>4 ng\u002FmL (unless cancer ruled out), active urinary tract infection, urinary retention, and those unavailable for follow-up were also excluded from the study.","45 Years",{"count":452,"type":21},90,[139],"This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs. 5 mg) on lower urinary tract symptoms (LUTS) severity and patient quality of life in men with benign prostatic hyperplasia (BPH). It also seeks to determine whether the lower tadalafil dose provides adequate symptom relief while minimizing adverse effects over a 12-week follow-up period.",[456,457,458,459,460,461,462],"Safety","Efficacy","Tamsulosin","Monotherapy","Tadalafil","Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia","2026-07-20",{"date":411,"type":36},{"date":466,"type":36},"2026-07-01",{"date":223,"type":21},{"name":42,"class":43},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":85,"enrollmentInfo":476,"targetDuration":4,"studyType":56,"phases":477,"briefSummary":478,"conditions":479,"keywords":483,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":44},"100595772","phase-2-effect-of-melatonin-in-patients-with-diabetic-peripheral-neuropathy-100595772","NCT07036796","Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy","Effect of Melatonin on the Clinical Outcomes in Type 2 Diabetic Patients With Peripheral Neuropathy","Inclusion Criteria:\n\n1. Patients aged 40-75 years diagnosed with type 2 DM.\n2. Diabetes duration at least 1 year.\n3. Patients diagnosed with diabetic peripheral neuropathy.\n4. Stable antidiabetic medication for at least 1 month before enrollment and during the trial\n\nExclusion Criteria:\n\n1. Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.\n2. Patients with severe kidney or liver dysfunction.\n3. Patients diagnosed with neurodegenerative diseases.\n4. Active infection.\n5. Use of medications or supplements known to cause or treat peripheral neuropathy.\n6. Alcohol consumption or substance abuse.\n7. Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment.\n8. Pregnancy or lactation or expecting to get pregnant during the study.\n9. Allergy to melatonin.",{"count":112,"type":21},[58],"The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.",[480,481,482],"Diabetic Peripheral Neuropathy","Diabetic Neuropathy","Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients",[484,485,486,487],"Diabetic peripheral neuropathy","Diabetic neuropathies","Diabetic neuropathy in type 2 diabetes","Melatonin",{"date":489,"type":36},"2026-07-21",{"date":491,"type":36},"2025-07-04",{"date":493,"type":21},"2027-07-04",{"name":42,"class":43},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":56,"phases":506,"briefSummary":507,"conditions":508,"keywords":511,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":518,"leadSponsor":520,"locationsCount":44},"100648439","phase-2-effect-of-melatonin-administration-on-systemic-lupus-erythematosus-patients-100648439","NCT07721324","Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients","Effect of Melatonin Administration on the Clinical Outcomes of Systemic Lupus Erythematosus Patients","SLE","Inclusion Criteria:\n\n* Adult male and female patients with active SLE aged 18-60 years\n* Active SLE patients defined on SLEDAI-2K score to be (more than or equal 4 up to 11) according to the classification of SLE as suggested by the American Rheumatology Association (American College of Rheumatology)\n* Have had non-life-threatening disease\n* Taking stable doses of medications for SLE treatment in the last three months\n* Ability and willingness to cooperate in the study\n\nExclusion Criteria:\n\n* Other autoimmune diseases\n* Uncontrolled hypertension or Uncontrolled DM\n* Severe renal (GFR \\\u003C 30 ml\u002Fmin ) or severe liver diseases (ALT or AST \\\u003C3 times ULN or total bilirubin \\> 2 times ULN)\n* Life-threatening SLE including\n\n  * Severe hemolysis (reticulocyte count \\>8%)\n  * Severe thrombocytopenia (platelet count \\\u003C40 000)\n  * Endocarditis\n  * Lupus pneumonia\n  * Alveolar hemorrhage\n* Using sedations, antidepressants, contraceptives, antioxidant and\u002For omega-3-fatty acid supplements one month prior to or during the study\n* Smoking and\u002F or alcohol intake\n* Allergy to melatonin\n* Pregnancy, pregnancy plans and lactation.\n* Having active infectious diseases\n* poor patient compliance\n* Any sleeping pills two weeks prior to the study\n* Malabsorption syndromes\n* Malignancy\n* Warfarin or heparin use or high-dose aspirin (more than 325 mg\u002Fday)\n* Stroke","60 Years",{"count":505,"type":21},64,[58,59],"The aim of the current study is to evaluate the effect of melatonin administration on circulating levels of inflammatory mediators, oxidative stress, sleep quality, fatigue and quality of life in patients with SLE. To the best of our knowledge, this is the first randomized-controlled trial to evaluate the impact of melatonin on sleep quality and assess fatigue and quality of life in SLE adult patients. Moreover, the impact of melatonin on serum concentrations of Interleukin-6 and superoxide dismutase SOD will be evaluated.",[509,510],"Therapy","Treatment",[487,512,191,513,514],"Systemic Lupus Erythematosus","Fatigue","SLEQoL","2026-07-18",{"date":411,"type":36},{"date":489,"type":21},{"date":519,"type":21},"2026-11-21",{"name":42,"class":43},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":528,"maxAge":18,"enrollmentInfo":529,"targetDuration":4,"studyType":56,"phases":530,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":542,"leadSponsor":544,"locationsCount":4},"100647800","evaluation-of-the-radioprotective-effect-of-3d-printed-intraoral-stents-in-children-with-brain-cancer-100647800","NCT07715357","Evaluation of The Radioprotective Effect of 3D-Printed Intraoral Stents in Children With Brain Cancer.","Evaluation of The Radioprotective Effect of 3D-Printed Intraoral Stents in Children With Brain Cancer: A Randomized Clinical Trial and An In-Vitro Study","Inclusion Criteria:\n\n1. Patients who will receive 5-7 weeks of definitive radiotherapy for treatment of a diagnosed medulloblastoma tumor.\n2. Age less than 18 years old.\n3. No Evidence of oral mucositis at baseline (WHO grade 0)\n\nExclusion Criteria:\n\n1. Patients with prior exposure to head and neck radiotherapy.\n2. Patients who are unable to wear oral stent.\n3. Patients with known allergies or hypersensitivity to dental resin materials.","6 Years",{"count":137,"type":21},[139],"Brain cancer patients undergoing radiotherapy may experience oral complications such as oral mucositis, gingival inflammation, plaque accumulation, radiation-induced caries, and reduced oral-health-related quality of life due to scatter radiation affecting oral tissues.\n\nAlthough intraoral stents are used to protect and reposition oral structures during radiotherapy, conventional stents lack standardization in material properties and thickness, leading to variable radioprotective effectiveness. Advances in 3D printing allow fabrication of customized resin intraoral stents with controlled thickness. However, there is not a lot of research in the literature about the materials that are employed as intraoral radiation stents to reduce the radiation dosage received by healthy tissue. Since these devices can lower radiation exposure to healthy tissues, the current study seeks to evaluate the degree of attenuation of therapeutic radiation with four different thicknesses for the intraoral stents and then assess the clinical effectiveness of the optimized thickness of the 3D-printed resin intraoral stent in reducing oral mucositis, periodontal health status, radiation induced caries, and in improving patient-reported outcomes in brain cancer patients undergoing radiotherapy.",[533],"Medulloblastoma Tumor",[535,536,537,538,539],"3D printing","Intraoral stents","Radiation protection","Pediatric Oncology","Radiotherapy",{"date":489,"type":36},{"date":99,"type":21},{"date":543,"type":21},"2028-08-01",{"name":42,"class":43},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":503,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":44},"100645854","internal-jugular-vein-collapsibility-index-as-a-predictor-of-hypotension-100645854","NCT07692425","Internal Jugular Vein Collapsibility Index as a Predictor of Hypotension","Internal Jugular Vein Collapsibility Index as a Predictor of Hypotension After The Induction of General Anesthesia in Geriatric Patients Undergoing Laparoscopic Colorectal Surgeries: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged ≥ 60 years.\n* Scheduled for elective laparoscopic colorectal surgeries under general anesthesia.\n\nExclusion Criteria:\n\n* Patients' refusal of procedure or participation in the study.\n* Severe aortic stenosis, irregular ventricular rhythm (atrial fibrillation or frequent premature ventricular contractions), or any contraindication to perform passive leg raise (PLR).",{"count":425,"type":21},"The internal jugular vein (IJV) collapsibility index has been proposed as a practical alternative of of the inferior vena cava collapsibility index (IVC-CI), as it is easily accessible using bedside ultrasonography. Several studies have demonstrated a correlation between IJV collapsibility and central venous pressure as well as right atrial pressure.",[555],"Intraoperative Hypotension","2026-07-17",{"date":463,"type":36},{"date":559,"type":36},"2026-07-11",{"date":561,"type":21},"2027-02-11",{"name":42,"class":43},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":528,"maxAge":18,"enrollmentInfo":569,"targetDuration":4,"studyType":56,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":4},"100647950","phase-2-efficacy-and-safety-of-spironolactone-in-pediatric-hemodialysis-patients-with-anemia-100647950","NCT07715318","Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia.","Inclusion Criteria:\n\n1. Male or female patients with ages 6-18 years old undergoing regular hemodialysis (3 sessions per week for at least 6 months)\n2. Pediatric patients weighing between 25 kg and 50 kg.\n3. Patients with potassium level less than 5.5 mmol\u002FL and produce urine.\n4. Anemic patients \"have Hb values between 9.5 and 12.5 g\u002Fdl, transferrin saturation (TSAT) less than 20%)\n5. patients have been receiving stable rHuEpo therapy administered intravenously (IV) or subcutaneously (SC) for at least 8 weeks prior to randomization\n6. Patients suffering from iron- restricted erythropoiesis -\n\nExclusion Criteria:\n\n1. Patients with acute renal insufficiency.\n2. Patients with hyperkalemia (≥5.5 mmol\u002FL) and hyponatremia (blood level less than135 mEq\u002FL)\n3. Patients with liver disease (AST \\& ALT greater than 3times upper limit normal)\n4. Patients with hypersensitivity to spironolactone.\n5. Patients scheduled for a living donor kidney transplant within 6 weeks following consent.\n6. Current or recently enrolled in another investigational drug study (within 30 days).\n7. Uncontrolled pre-dialysis supine diastolic blood pressure greater than the 95th percentile for height, gender, and age on more than two occasions in the 2 weeks prior to screening.\n\n   \\-",{"count":570,"type":21},40,[58],"The goal of this clinical trial is to learn if Spironolactone drug works to treat anemia in hemodialysis pediatric patients. It will also learn about the safety of Spironolactone drug. The main questions it aims to answer are:\n\nIn pediatric patients with anemia undergoing maintenance hemodialysis, does treatment with spironolactone, compared with standard care alone, reduce erythropoietin dose requirements while maintaining an acceptable safety profile? Researchers will compare Spironolactone drug to a standard therapy ((IV iron according to serum iron deficiency and patient's weight, epoetin after each session of dialysis according to the patient's weight) to see if Spironolactone drug works to treat anemia.\n\nParticipants will:\n\n* Take Spironolactone drug daily for 12 weeks in addition to standard care.\n* Continue their scheduled maintenance hemodialysis sessions.\n* Undergo regular monitoring during dialysis visits, including clinical assessment and laboratory tests (e.g., hemoglobin, potassium, renal profile)\n* Record any symptoms or side effects during the study period.",[574],"Anemia",[576,577,578,579,580,581,582],"Spironolactone","pediatric hemodialysis","chronic kidney disease","end stage renal disease","anemia","erythropoietin","hemodialysis patients",{"date":463,"type":36},{"date":585,"type":21},"2026-12-01",{"date":587,"type":21},"2028-03-01",{"name":42,"class":43},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":281,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":56,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":44},"100647376","effect-of-theravex-tissue-care-on-implant-stability-100647376","NCT07707388","Effect of Theravex Tissue Care on Implant Stability","Effect of Theravex Tissue Care on Implant Stability in Immediate Implant Placement: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patient requires extraction of a single failing or non-restorable maxillary anterior tooth or premolar.\n* Presence of an intact buccal bone plate (Socket Type I) with a horizontal peri-implant jumping gap ≥ 2 mm.\n* The implant can be placed in an ideal 3-D position with an intraoperative primary stability target of ≥ 35 Ncm.\n* Patient is in good general health with no systemic contraindications to implant surgery.\n* Patient is cooperative and available for the entire 6-month follow-up period\n\nExclusion Criteria:\n\n* Pregnant and lactating females.\n* Heavy smokers (smoking ≥ 10 cigarettes per day).\n* Patients with poor oral hygiene.\n* Patients with occlusal or malalignment problems.\n* Patients with parafunctional habits (e.g., bruxism).",{"count":20,"type":21},[139],"The aim of this randomized clinical trial is to evaluate the clinical and radiographic outcomes of using Bone Bioactive Liquid (Theravex) compared to Xenograft and a combination therapy (Theravex + Xenograft) during immediate implant placement in the esthetic zone.\n\nWhen a tooth is extracted and replaced immediately with a dental implant, bone grafting is often necessary to fill the gap (jumping distance) between the implant and the surrounding bone socket to support tissue healing and maintain facial contour.\n\nParticipants requiring immediate implant placement will be randomly assigned into three groups:\n\nGroup 1: Immediate implant placement using Bone Bioactive Liquid (Theravex).\n\nGroup 2: Immediate implant placement using Xenograft alone.\n\nGroup 3: Immediate implant placement using Combination Therapy (Theravex + Xenograft).\n\nThe primary outcomes will evaluate implant stability, bone dimensional changes, and soft tissue response around the implants over the follow-up period.",[600],"Immediate Dental Implant Placement",[602,603,604,605,606,607,608],"immediate","implant","gap","jumping","socket","theravex","xenograft","2026-07-14",{"date":611,"type":36},"2026-07-16",{"date":613,"type":21},"2026-11-12",{"date":615,"type":21},"2027-09-08",{"name":42,"class":43},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":355,"enrollmentInfo":624,"targetDuration":4,"studyType":56,"phases":625,"briefSummary":626,"conditions":627,"keywords":629,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":634,"leadSponsor":636,"locationsCount":44},"100641649","palmitoylethanolamide-in-ulcerative-colitis-100641649","NCT07609810","Palmitoylethanolamide in Ulcerative Colitis","The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients","Inclusion Criteria:\n\n* Confirmed diagnosis of ulcerative colitis (UC) by established clinical and endoscopic criteria.\n* Active mild-to-moderate UC patients defined by a SCCAI score ≥ 5 and \\\u003C 12 at screening, not responding to 5-aminosalicylates (5-ASA) defined as persistent rectal bleeding beyond 2 weeks or failure to achieve sustained symptom relief after 40 days of appropriate 5-ASA therapy, steroid-dependent defined as unable to reduce steroids below the equivalent of prednisolone 10 mg\u002Fday or budesonide below 3 mg\u002Fday within 3 months of starting steroids, without recurrent active disease or who have a relapse within 3 months of stopping steroids and they currently take azathioprine.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Alcohol or drug abuse.\n* Allergy or known hypersensitivity to palmitoylethanolamide.\n* Active infection (enteric or systemic).\n* Uncontrolled metabolic\u002F neurologic conditions: uncontrolled hypertension, uncontrolled diabetes, migraine disorders or other uncontrolled neurologic disease.\n* Other autoimmune diseases.\n* Severe or acute severe colitis requiring hospitalization.\n* UC patients requiring colectomy.\n* Crohn disease (CD), chronic pancreatitis, cholecystitis or other inflammatory conditions involving the gastrointestinal tract (GIT).\n* Patients with renal or liver disease.\n* Patients who have never been treated for UC.\n* Any patients on biologics.\n* Patients using NSAIDs or aspirin (due to interference with fecal calprotectin results).",{"count":112,"type":21},[139],"Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.",[628],"Ulcerative Colitis (UC)",[630],"palmitoylethanolamide - endocannabinoid - disease activity","2026-07-13",{"date":609,"type":36},{"date":33,"type":21},{"date":635,"type":21},"2029-02-15",{"name":42,"class":43},""]